Intravitreal Ranibizumab for Choroidal Neovascularization With Large Submacular Hemorrhage in Age-Related Macular Degeneration

Iacono, Pierluigi; Parodi, Maurizio Battaglia; Introini, Ugo; Spina, Carlo La; Varano, Monica; Bandello, Francesco

doi:10.1097/iae.0b013e3182979e33

Cited by 34 publications

(22 citation statements)

References 25 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Our patients had a larger mean SMH area at baseline compared to those in previous studies; however, our results are comparable with those of previous studies with respect to SMH prognostic factors. 1,13,17 In cases with expected poor prognosis at baseline, other treatment options (pneumatic displacement or rTPA administration) should also be considered over or in combination with anti-VEGF therapy. However, there are few studies evaluating the efficacy of pneumatic displacement and/or rTPA, particularly for large SMH.…”

Section: Discussionmentioning

confidence: 99%

Intravitreal anti-vascular endothelial growth factor monotherapy for large submacular hemorrhage secondary to neovascular age-related macular degeneration

Kim

Cho

Yoo

et al. 2015

Eye

View full text Add to dashboard Cite

Section: Discussionmentioning

confidence: 99%

Intravitreal anti-vascular endothelial growth factor monotherapy for large submacular hemorrhage secondary to neovascular age-related macular degeneration

Kim

Cho

Yoo

et al. 2015

Eye

View full text Add to dashboard Cite

“…However, limited published data are available regarding its efficacy in predominantly hemorrhagic lesions due to CNV [23,29,30]. In a prospective interventional case series on 22 eyes with predominantly hemorrhagic CNV, Iacono et al demonstrated a significant improvement in BCVA (p = 0.04), even if only 6 patients presented with foveal involvement at baseline [23]. …”

Section: Discussionmentioning

confidence: 99%

“…Treatment was given according to standard practice with an initial loading phase of 3 monthly injections of 0.5 mg/0.05 ml ranibizumab, followed by a maintenance phase with further assessment every month, with repeated injections as judged necessary by the treating ophthalmologist on the basis of the detection of subretinal fluid or intraretinal fluid on OCT, leakage on FA, a BCVA reduction of ≥5 ETDRS letters and the appearance of any new hemorrhages on fundus examination [23]. …”

Section: Methodsmentioning

confidence: 99%

Intravitreal Ranibizumab for Predominantly Hemorrhagic Choroidal Neovascularization in Age-Related Macular Degeneration

et al. 2015

Self Cite

View full text Add to dashboard Cite

Purpose: To evaluate the effects of intravitreal ranibizumab monotherapy on predominantly hemorrhagic choroidal neovascularization with foveal involvement associated with age-related macular degeneration. Materials and Methods: Twenty-two consecutive eyes with hemorrhagic neovascularization were treated with 3 monthly intravitreal ranibizumab injections. Additional injections were administered according to retreatment criteria during 12 months of follow-up. Results: A mean of 6.64 ± 1.36 injections was administered. Overall, the mean visual acuity increased from 10.90 ± 6.02 to 12.81 ± 8.34 ETDRS letters (p > 0.05) at 12 months. The ‘early treatment group' gained a mean of 2.83 ± 2.24 ETDRS letters (p < 0.05), while the ‘late treatment group' gained a mean of 0.30 ± 1.25 ETDRS letters (p > 0.05) with significant differences between the groups (p < 0.05). A progressive resolution of macular bleeding was registered in 20 patients (mean time: 5.3 ± 1.6 months). Conclusions: Ranibizumab injections can be considered a beneficial approach for the management of predominantly hemorrhagic choroidal neovascularization with foveal involvement associated with age-related macular degeneration. Furthermore, the time interval between hemorrhage and the first injection seems to be an important predicting factor of final visual acuity.

show abstract

“…These two eyes were treated with either pneumatic displacement or intravitreal anti-VEGF monotherapy, both of which have been shown to be effective in treating submacular hemorrhage secondary to exudative AMD [19][20][21][22][23][24]. However, visual acuity failed to return to baseline values in both patients.…”

Section: Discussionmentioning

confidence: 99%

Two-year Outcomes after Intravitreal Anti-vascular Endothelial Growth Factor Therapy for Polypoidal Choroidal Vasculopathy Patients with Good Initial Visual Acuity

Yoo

Kim

Han

et al. 2017

J Retin

View full text Add to dashboard Cite

Purpose:To investigate 2-year treatment outcomes of anti-vascular endothelial growth factor (VEGF) therapy in eyes with polypoidal choroidal vasculopathy (PCV) with good baseline visual acuity. Methods: This retrospective, observational study included 21 eyes (10 eyes with a subfoveal polyp, 11 eyes with an extrafoveal polyp) of 21 subjects diagnosed with PCV. All eyes had a baseline best-corrected visual acuity (BCVA) of 20/25 or better and were administered an initial treatment of three intravitrial anti-VEGF injections at one-month intervals. Additional anti-VEGF treatments were administered as needed for recurring cases. BCVA and central foveal thickness (CFT) obtained 24 months after diagnosis were compared with baseline values. Results: Mean logarithm of the minimal angle of resolution (logMAR) BCVA was 0.07 ± 0.04 at baseline and 0.19 ± 0.29 approximately 24 months after initial diagnosis, a slight difference that was not statistically significant (p = 0.560). Of the 21 eyes included, 17 eyes (80.9%) had stable vision and 4 eyes (19.0%) had a ≥0.2 deterioration in logMAR BCVA. Twenty-four-month CFT (212.9 ± 76. 1 µm) was significantly lower than baseline CFT (324.6 ± 121.2 µm, p = 0.015). Conclusions: Two-year visual outcomes following anti-VEGF therapy in eyes with PCV and good initial visual acuity were generally favorable. However, logMAR BCVA deteriorated by ≥0.2 in 19.0% of treated eyes.

show abstract

Intravitreal Ranibizumab for Choroidal Neovascularization With Large Submacular Hemorrhage in Age-Related Macular Degeneration

Abstract: Intravitreal ranibizumab can be considered a beneficial approach for the management of choroidal neovascularization with flat large submacular hemorrhage secondary to age-related macular degeneration.

Cited by 34 publications

References 25 publications

Intravitreal anti-vascular endothelial growth factor monotherapy for large submacular hemorrhage secondary to neovascular age-related macular degeneration

Intravitreal anti-vascular endothelial growth factor monotherapy for large submacular hemorrhage secondary to neovascular age-related macular degeneration

Intravitreal Ranibizumab for Predominantly Hemorrhagic Choroidal Neovascularization in Age-Related Macular Degeneration

Two-year Outcomes after Intravitreal Anti-vascular Endothelial Growth Factor Therapy for Polypoidal Choroidal Vasculopathy Patients with Good Initial Visual Acuity

Contact Info

Product

Resources

About